Industry News (Patents and Technology)

University of Texas System Awarded Patent for p16 Gene Therapy

Published in Gene Therapy Weekly, December 22nd, 1997

The Board of Regents of The University of Texas System (UT) and Introgen Therapeutics, Inc., Austin, Texas, announced that the U.S. Patent and Trademark Office has issued to UT a U.S. patent, entitled "p16 Expression, Constructions, and Their Application in Cancer Therapy," which covers adenoviral expression constructs that carry a p16 tumor suppressor gene intended for gene-based therapeutics.

This patent is one of numerous intellectual properties owned by The Board of Regents of UT and licensed exclusively to Introgen Therapeutics, Inc. through Introgen's broad license agreement with UT's M.D. Anderson Cancer Center (UTMDACC). The p16 gene...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-12-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry